M&A / Deal

✒ The walk-away was due to last minute dispute over the underfunded pension obligation.

✒ The rationale of the deal is “to bol­ster its of­fer­ings and make it­self more at­trac­tive to in­vestors ahead of an even­tual IPO”.

✒ Does The We Company worth $47 billion, $23 billion, or $36 billion?

✒ The second multi-billion dollar healthcare deal of 2019, and it’s only the second week of the year.

✒ An audacious deal to kick off the year.

✒ Shifting towards the value-based reimbursement models.

✒ The go-shop clause was a nice touch.

✒ “The partners want to load the business with net debt worth 3.5 to 4 times earnings before interest, taxes, depreciation and amortization before the spinoff, making it among the most highly leveraged consumer assets… the plan will only work out if the business is in good health. Even more than most deals, this one … Read More

Pfizer, Glaxo to Create Over-the-Counter Drug GiantThe deal will free up both to concentrate on prescription medicines, which tend to be more profitable, though higher risk